Publication|Articles|February 11, 2025
Supplements and Featured Publications
- Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis
Role of Spevigo® (spesolimab-sbzo) Injection in the Treatment of Generalized Pustular Psoriasis
Listen
0:00 / 0:00
This Clinical Brief is supported by Boehringer Ingelheim.
This article provides an overview of generalized pustular psoriasis (GPP) and its clinical and economic impact, and reviews findings of Effisayil® 2, the first trial to study subcutaneous Spevigo® (spesolimab-sbzo) in patients with GPP when not experiencing a flare.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Latest CME
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
5